Menu
Joint Clinical Trials Office

You are here

Home
Among psychiatric nurses what are the levels of RN engagement and what are the relationships between each driver of engagement and RN engagement?
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 29, 2017
Among psychiatric nurses what are the levels of RN engagement and what are the relationships between each driver of engagement and RN engagement?
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 29, 2017
A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission with Minimal Residual Disease
Study Status:
Open to Enrollment
Primary Investigator:
Ellen Ritchie M.D.
Date: December 11, 2017
A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission with Minimal Residual Disease
Study Status:
Open to Enrollment
Primary Investigator:
Ellen Ritchie M.D.
Date: December 11, 2017
A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission with Minimal Residual Disease
Study Status:
Open to Enrollment
Primary Investigator:
Ellen Ritchie M.D.
Date: December 11, 2017
A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission with Minimal Residual Disease
Study Status:
Open to Enrollment
Primary Investigator:
Ellen Ritchie M.D.
Date: December 11, 2017
A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission with Minimal Residual Disease
Study Status:
Open to Enrollment
Primary Investigator:
Ellen Ritchie M.D.
Date: December 11, 2017
A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission with Minimal Residual Disease
Study Status:
Open to Enrollment
Primary Investigator:
Ellen Ritchie M.D.
Date: December 11, 2017
A PHASE 2B RANDOMISED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, PARALLEL ADAPTIVE 2‐STAGE, MULTICENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL PTG‐100 INDUCTION IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS (PROPEL)
Study Status:
Open to Enrollment
Primary Investigator:
Ellen Scherl, MD
Date: September 5, 2017
A PHASE 2B RANDOMISED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, PARALLEL ADAPTIVE 2‐STAGE, MULTICENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL PTG‐100 INDUCTION IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS (PROPEL)
Study Status:
Open to Enrollment
Primary Investigator:
Ellen Scherl, MD
Date: September 5, 2017